Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Clene Inc (CLNN)

Clene Inc (CLNN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,042
  • Shares Outstanding, K 10,850
  • Annual Sales, $ 340 K
  • Annual Income, $ -39,400 K
  • EBIT $ -24 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.81
  • Price/Sales 195.70
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.53
  • Low Estimate -0.95
  • Prior Year -1.67
  • Growth Rate Est. (year over year) +55.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.88 +21.91%
on 02/04/26
5.43 -12.89%
on 01/22/26
-0.32 (-6.34%)
since 01/16/26
3-Month
3.88 +21.91%
on 02/04/26
10.84 -56.37%
on 12/01/25
-3.92 (-45.32%)
since 11/19/25
52-Week
2.28 +107.45%
on 05/23/25
13.50 -64.96%
on 11/03/25
-0.01 (-0.21%)
since 02/19/25

Most Recent Stories

More News
Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)
Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting

The FDA has granted an in-person Type C meeting during the first quarter of 2026  New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly...

CLNN : 4.73 (+4.65%)
Clene Announces Registered Direct Offering of Over $28 Million

Oversubscribed registered direct offering priced above market to new, existing and insider investors, including Boxer Capital Management, Coastlands Capital, and Vivo Capital Initial financing tranche...

CLNN : 4.73 (+4.65%)
Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)
Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival,...

CLNN : 4.73 (+4.65%)
Clene to Provide CNM-Au8® ALS Program Update

SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)
Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)
Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly  The FDA advised Clene to request a Type C meeting to...

CLNN : 4.73 (+4.65%)
Clene to Present at the Emerging Growth Conference

SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical...

CLNN : 4.73 (+4.65%)

Business Summary

Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I Limited, is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 5.48
2nd Resistance Point 5.16
1st Resistance Point 4.94
Last Price 4.73
1st Support Level 4.40
2nd Support Level 4.08
3rd Support Level 3.86

See More

52-Week High 13.50
Fibonacci 61.8% 9.21
Fibonacci 50% 7.89
Fibonacci 38.2% 6.57
Last Price 4.73
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar